

Recombinant 41 kDa-B flagellin for Borrelia burgdorferi

CATALOG NUMBER: RAG0055

LOT NUMBER: #

RECOMBINANT ANTIGEN: internal central portion of *B. burgdorferi* 41 kDa flagellar protein, flagellin B (Jiang *et al.*, 1992).

DESCRIPTION: the central region of the *Borrelia burgdorferi* flaB gene has been expressed as a recombinant antigen fused to a TrxA and a his-tag in its N-terminus.

PRESENTATION: liquid protein solution

SOURCE: Escherichia coli

MOLECULAR WEIGHT: determined by SDS-PAGE, the protein band is between molecular markers of 25,000 and 35,000 Da, while relative molecular mass calculated from amino acid sequence is 25.638,61 Da.

BATCH COMPOSITION:

COMPONENTS	COMPOSITION
TrxA-his-flaB	recombinant antigen fragment
Storage buffer	20 mM phosphate buffer pH 7, 0.15 M NaCl and 0.1% polyoxyethylene (10) tridecyl ether

QUALITY CONTROL:

1. PROTEIN CONCENTRATION DETERMINED ESPECTROPHOTOMETRICALLY

 $DO_{280} = 1.09$

A $_{0.1}$ % (=1 g/l) = 0.881

CONCENTRATION*: 1.24 mg/ml

2. PURITY CONTROL IN SDS-PAGE: 15%




Figure 1. SDS-PAGE analysis (15%) of 8 μ l of recombinant flagellin B Bb. Purity is approx. 95% as determined by gel electrophoresis.

3. ABSENCE OF PRECIPITATION AFTER A FREEZING AND THAWING CYCLE: ok

LOT SPECIFICATIONS:

1. CONCENTRATION: 1.24 mg/ml

2. TOTAL QUANTITY PER ALIQUOT: 1 mg

3. TOTAL VOLUME PER ALIQUOT: 0.846 ml

4. STORAGE: Protein is shipped with dry ice. Upon arrival, it should be aliquoted to avoid repeated freezing and thawing cycles and stored at -20°C to -80°C. In order to defrost the protein, maintain the aliquot at 25°C without shaking to avoid aggregation.

5. TESTED APPLICATIONS: none.

6. POSIBLE APPLICATIONS: WB, DB, Indirect ELISA, positive control in direct ELISA, CLIA, lateral-flow. Where this product has not been tested for use in a particular technique, this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates.

7. OBSERVATIONS: in some cases, purified proteins run at a molecular weight which is slightly different to the theoretically calculated molecular weight maybe due to the his-tag presence, which can produce a delay in SDS-PAGE. Proteins should be maintained frozen at high concentrations. The dilution to be performed for ELISA assays should be made with a small quantity of protein, the same day of the experiment. In order to defrost the protein, maintain the aliquot at 25°C without shaking to avoid aggregation. Prior making test dilutions and after defrost the protein, is recommended to remove possible protein aggregates by centrifuging the stock solution, avoiding alterations in the immobilization of the biomolecule to the solid surface.

RELATED PRODUCTS:

Flagellin B Bg, Flagellin B Ba, ospC Ba, ospC Bb, ospC Bg, VIsE Bg, VIsE Ba, ChimLyme Bb.

BIBLIOGRAPHY:

Jiang, W. Luft, B.J., Schubach, W., Dattwyler, R.J. and P.D. Gorevic. Mapping the Major Antigenic Domains of the Native Flagellar Antigen of Borrelia burgdorferi. 1992, Journal of Clinical Microbiology, 30:1535-1540.

Gill SC, von Hippel PH. Calculation of protein extinction coefficients from amino acid sequence data. *Anal Biochem.* 1989 Nov 1;182(2):319-26.



Page 1 of 2

^{*} The measurement of the protein concentration has been performed with the theoretical extinction coefficient of the recombinant protein obtained from Gill and vonHippel, 1989. It is recommended that the users carry out their absorbance determinations to avoid equipment variabilities regarding final concentration, mainly in reproducibility analysis.

rekom

Important Notes: During shipment, small volumes of product will occasionally become entrapped in the seal of the product vial. For products with volumes of 200 µl or less, we recommend gently tapping the vial on a hard surface or briefly centrifuging the vial in a tabletop centrifuge to dislodge any liquid in the containers cap.

Although recombinant antigens are expressed in non-pathogenic E. *coli* and bacterial integrity is destroyed during purification, the antigen preparation should be handled as potentially infectious.

FOR RESEARCH AND COMMERCIAL USE IN VITRO: not for human in vivo or therapeutic use.

